[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial

Autor:	H. Adams, E. M. W. van de Garde, D. J. Vugts, J. C. Grutters, Wim. J.G. Oyen, R. G. Keijsers
Přispěvatelé:	Pharmacoepidemiology and Clinical Pharmacology, Sub Molecular Microbiology, Afd Pharmacoepi & Clinical Pharmacology, Radiology and nuclear medicine, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers
Rok vydání:	2023
Předmět:	All institutes and research themes of the Radboud University Medical Center Radiology Nuclear Medicine and imaging PET-CT 89Zr-rituximab Radiology Nuclear Medicine and imaging CD20 Interstitial lung disease General Medicine Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] Rituximab Immuno PET
Zdroj:	European Journal of Nuclear Medicine and Molecular Imaging, 50, 7, pp. 1929-1939 Adams, H, van de Garde, E M W, Vugts, D J, Grutters, J C, Oyen, W J G & Keijsers, R G 2023, ' [89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis : a phase 2 trial ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 7, pp. 1929-1939 . https://doi.org/10.1007/s00259-023-06143-1 European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 1929-1939. Springer Verlag European Journal of Nuclear Medicine and Molecular Imaging, 50, 1929-1939
ISSN:	1619-7070
DOI:	10.1007/s00259-023-06143-1
Popis:	Introduction Immune-mediated interstitial pneumonitis may be treated with anti-CD20 therapy after failure of conventional therapies. However, clinical response is variable. It was hypothesized that autoreactive CD20-positive cells may play an important role in this variability. This prospective study aims to elucidate if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment. Methods Twenty-one patients with immune-mediated interstitial lung disease (ILD) with deteriorated pulmonary function received a dose of 1000 mg rituximab on day 1 and day 14 spiked with a tracer dose of radiolabeled [89Zr]-rituximab. PET/CT was performed on days 3 and 6. Standardized uptake values (SUV) were calculated as a measure for pulmonary CD20 expression. Based on pulmonary function tests (PFT), forced vital capacity (FVC), and diffusing capacity for carbon monoxide (DLCO), prior to and 6 months after treatment, patients were classified as responder (stable disease or improvement) or non-responder. Results Fifteen patients (71%) were classified as responder. Pulmonary [89Zr]-rituximab PET SUVmean was significantly correlated with the change in FVC and DLCO (K = 0.49 and 0.56, respectively) when using target-to-background ratios, but not when using SUVmean alone. [89Zr]-rituximab SUVmean was significantly higher in responders than in non-responders (0.35 SD 0.09 vs. 0.23 SD 0.06; P = 0.02). Conclusion Rituximab treatment was effective in the majority of patients. As a higher pulmonary uptake of [89Zr]-rituximab correlated with improvement of PFT and treatment outcome, [89Zr]-rituximab PET imaging may serve as a potential predictive biomarker for anti-CD20 therapy. Trial registration Clinicaltrials.gov identifier NCT02251964
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95043d7e69cab1fc39c96074c916003e https://hdl.handle.net/2066/293176 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.